HOME >> MEDICINE >> NEWS
Newer diabetic meds cost more, but users have fewer hospital visits

Diabetics who were prescribed newer medications to control their illness were more likely to take these drugs as instructed than were other patients who were prescribed drugs that have been on the market for several decades.

A new study suggests that patients on the newer medications had a slightly lower risk of hospitalization because of diabetes-related complications. They also spent between $920 and $1,760 less on annual total healthcare costs.

The researchers analyzed more than three years' worth of medical records' data on patients who took thiazolidinediones (TZDs) or either metformin or a sulfonylurea to control their diabetes. TZDs (pioglitazone and rosiglitazone, brand names Actos and Avandia, respectively), were approved by the Food and Drug Administration in the late 1990s. Metformin and sulfonylureas have been on the market for more than 50 years.

"Taking a TZD as instructed was the strongest predictor of a reduced risk of hospitalization and decreased healthcare costs in this group of patients," said Rajesh Balkrishnan, the study's lead author and the Merrell Dow professor of pharmacy at Ohio State University.

The issue is that TZDs can be 10 times more expensive than the older diabetes drugs, Balkrishnan said.

"There are a lot of new medications on the market for treating diabetes," Balkrishnan said. "Although some of these newer drugs are more expensive, that extra expense is made up for by a reduction of cost in other aspects of healthcare use."

The study appears in a recent issue of the journal Current Medical Research and Opinion.

The researchers collected information on 3,191 adults enrolled in the North Carolina Medicaid program, which covers all medical and prescription costs of its enrollees. All of the participants had Type 2 diabetes and started medications for the disease between July 2001 and December 2003.

The enrollees were divided into two groups based on the type of drug th
'"/>

Contact: Rajesh Balkrishnan
Balkrishnan.1@osu.edu
614-292-6415
Ohio State University
21-Mar-2006


Page: 1 2 3

Related medicine news :

1. Newer biomarkers add small improvement in cardiovascular risk prediction to established risk factors
2. Newer chemotherapies improve outcomes for some types of breast cancer
3. Newer form of cardiac imaging providing better look at heart
4. Newer imaging techniques may lead to over-treatment
5. Researchers find vitamin B1 deficiency key to vascular problems for diabetic patients
6. When it comes to preventing amputation in diabetics, site, not size, matters
7. Long-term anti-clotting therapy sweetens stenting outcomes in diabetic patients
8. UW study tests topical honey as a treatment for diabetic ulcers
9. Simple classification can help define and predict limb-threatening diabetic infections
10. Glucose levels trigger compensation for type 2 diabetics
11. Drug treatment slows macular vision loss in diabetics

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Newer diabetic meds cost more but users have fewer hospital visits

(Date:10/31/2014)... effort by the National Institutes of Health will ... to reframe mental health research, from diagnosis to ... recently established by the National Institute of Mental ... development of the institute,s RDoC initiative. , ... accelerate the pace of research that translates basic ...
(Date:10/31/2014)... News) -- A comparison of two of the most ... gastric bypass helped patients shed more excess pounds than ... short-term complications and long-term hospitalizations. Gastric-bypass surgery makes ... your body does not absorb all the calories from ... Health. Gastric banding is a type of weight-loss procedure ...
(Date:10/31/2014)... Steven Reinberg HealthDay Reporter THURSDAY, ... increase slightly the risk of broken bones and injured joints, a ... found that among 7 percent of people who had an eczema ... joint injury and 0.6 percent had an injury that caused a ... with the skin condition had more than double the risk of ...
(Date:10/30/2014)... one day provide new treatments for injuries and damage ... , Cartilage, for example, is a hard material that ... work smoothly. UC Davis biomedical engineers, exploring ways to ... outside the body, report new developments this week in ... Sciences . , "The problem with engineered tissue is ...
(Date:10/30/2014)... , A mathematical model developed by NIH grantees predicts ... to prevent HIV infection via vaginal sex, whereas just ... infection via anal sex. This finding helps explain why ... PrEP, in women failed to show efficacy. Participants in ... of Truvada and tenofovir (another antiretroviral) for HIV prevention ...
Breaking Medicine News(10 mins):Health News:NIMH creates new unit to support its research domain criteria initiative 2Health News:Study Compares 2 Common Weight-Loss Surgeries 2Health News:Study Compares 2 Common Weight-Loss Surgeries 3Health News:Eczema Tied to Bone Fracture Risk in Study 2Health News:Making lab-grown tissues stronger 2Health News:Model by NIH grantees explains why HIV prevention dosing differs by sex 2
(Date:10/31/2014)... LONDON , October 31, 2014 ... (NYSE: MDT ), Abbott Laboratories (NYSE: ... Inc. (NYSE: RMD ), and Covidien PLC (NYSE: ... at: http://investor-edge.com/register . The US markets on ... the Dow Jones Industrial Average finished at 17,195.42, up 1.30% ...
(Date:10/31/2014)... Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, ... 30, 2014. Brian M. Culley, the ... productive for Mast. Consistent with prior guidance, our 388-patient pivotal ... is on track to complete enrollment by the end ... in the U.S. and more than ten study sites ...
(Date:10/31/2014)... , October 31, 2014 ... a clinical-stage pharmaceutical company focused on the development ... company will host a conference call to discuss ... trial of ORMD-0801, the company,s proprietary oral insulin ... November 3, 2014 at 10:00 a.m. Eastern time. ...
Breaking Medicine Technology:Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 2Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 3Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 4Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 5Mast Therapeutics Reports Third Quarter 2014 Financial Results 2Mast Therapeutics Reports Third Quarter 2014 Financial Results 3Mast Therapeutics Reports Third Quarter 2014 Financial Results 4Mast Therapeutics Reports Third Quarter 2014 Financial Results 5Mast Therapeutics Reports Third Quarter 2014 Financial Results 6Mast Therapeutics Reports Third Quarter 2014 Financial Results 7Mast Therapeutics Reports Third Quarter 2014 Financial Results 8Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3
Cached News: